PORTFOLIO NEWS A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients March 2, 2022 Read More » NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results March 1, 2022 Read More » Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress February 28, 2022 Read More » Plexium Announces $102M Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform February 23, 2022 Read More » Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth February 17, 2022 Read More » Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs February 15, 2022 Read More » NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration February 7, 2022 Read More » Plexium and Amgen Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies February 3, 2022 Read More » Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors February 3, 2022 Read More » Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update January 27, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients March 2, 2022 Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results March 1, 2022 Read More »
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress February 28, 2022 Read More »
Plexium Announces $102M Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform February 23, 2022 Read More »
Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth February 17, 2022 Read More »
Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs February 15, 2022 Read More »
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration February 7, 2022 Read More »
Plexium and Amgen Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies February 3, 2022 Read More »
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors February 3, 2022 Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update January 27, 2022 Read More »
